Partner News | Published: Wednesday, February 28, 2024
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, is excited to announce an industry partnership with Cleerly®, a company on a mission to eliminate heart attacks by creating a new standard of care to aid in the diagnosis of heart disease. Through its FDA-cleared solutions driven by artificial intelligence (AI), Cleerly supports comprehensive phenotyping of coronary artery disease (CAD), as determined from advanced non-invasive computed tomography (CT) imaging.
“It’s an exciting time in the advancement of imaging technology, and Cleerly’s AI solution, with its vessel-by-vessel level of detail, has been at the forefront in the evaluation of CAD,” said Joe Sasson, PhD, MedAxiom’s EVP of Ventures and Chief Commercial Officer. “We are excited to welcome this powerful solution to the MedAxiom community, helping our members to better identify appropriate interventions, improve patient care, and be more competitive in a value-based world.”
Cleerly’s coronary AI-based analysis provides actionable insights for physicians that go beyond traditional coronary CT angiography scans with detailed vessel-by-vessel evaluation of stenoses, ischemia and atherosclerosis. Cleerly describes total plaque volume or percent atheroma volume in a way that is understandable to each stakeholder in the care pathway.
"We are thrilled to announce our partnership with MedAxiom, a collaboration empowering us to extend our innovative AI solutions for heart disease to their many members,” said James P. Earls, MD, Chief Medical Officer of Cleerly “We look forward to engaging with MedAxiom's members on our Cleerly product suite, educating them on the benefits of our technology and sharing the success stories of our disease model. We are committed to demonstrating the transformative impact our solutions continue to have on personalized heart health."
Cleerly’s approach is grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multicenter clinical trials. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.
About MedAxiom
MedAxiom, an American College of Cardiology Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.
About Cleerly®
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Cleerly’s approach is grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multicenter clinical trials. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: www.cleerlyhealth.com.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
